Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, May 4, 2016

Zinbryta (daclizumab HYP) is favored for approval in Europe


Click here to receive MS news via e-mail        

May 4, 2016

he Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently recommended marketing authorization to Zinbryta (daclizumab) for the treatment of patients with relapsing multiple sclerosis (RMS).
Zinbryta (daclizumab HYP) is a humanized monoclonal antibody that is injected every four weeks, and being developed by Biogen and AbbVie. It binds to the receptor subunit CD25 of interleukin-2 (IL-2), which is highly expressed in immune T-cells. These immune cells are overly expressed in MS, and Zinbryta is thought to deplete the activated T-cells and increase other cells that regulate the immune response (NK cells). The compound is currently under regulatory review in the United States, Canada, Australia, and Switzerland.
“For people with relapsing forms of MS (RMS) and active disease, ZINBRYTA has the potential to offer robust efficacy, a manageable safety profile through patient monitoring, and once-monthly subcutaneous dosing,” said Alfred Sandrock, MD, PhD, executive vice president and chief medical officer at Biogen, in a recent press release. “ZINBRYTA may offer another option for people with multiple sclerosis (MS) with its targeted mechanism of action (MOA) which did not cause broad and prolonged immune cell depletion.”
The European Commission (EC) will now review the CHMP positive opinion, and make its decision in the coming months.

MS Views and News
Provides educational information, resources and services for those affected by MS
We Believe YOU (the MS Patients and Caregivers) should Be Empowered with Multiple Sclerosis information

No comments: